je.st
news
Allergan Cost Synergies On Track For Large Upside
2015-03-15 01:50:25| Biotech - Topix.net
AGN is positioned well to take advantage of attractive industry growth; we believe management is conservative about its estimates on revenue projections. After the $66 billion dollar Activis and Allergan deal, post merger synergies will arise.
Tags: large
track
cost
upside
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||